drugset
drugset / Trial / NCT05093998

Study Evaluating the Efficacy and Safety of AV5080 in Patients With Uncomplicated Influenza

NCT05093998 ↗

Phase 3 Unknown 700 enrolled Viriom
RandomizedParallel-groupSingle-blindTreatment

Summary

To evaluate the efficacy of AV5080 versus Placebo based on time to symptom resolution in patients with uncomplicated influenza.

Timeline

Start
2022-01-15
Primary completion
2023-07-15
Completion
2023-07-31

Drugs

EvaluationDrugModalityDoseRoute
Subject AV5080 Unknown 160 mg Oral

Indications

influenza